0001209191-21-030171.txt : 20210504 0001209191-21-030171.hdr.sgml : 20210504 20210504210900 ACCESSION NUMBER: 0001209191-21-030171 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210430 FILED AS OF DATE: 20210504 DATE AS OF CHANGE: 20210504 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SIMPSON CAMILLA V CENTRAL INDEX KEY: 0001822557 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39594 FILM NUMBER: 21890843 MAIL ADDRESS: STREET 1: 20 ELAINE AVE. CITY: MILL VALLEY STATE: CA ZIP: 94941 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SPRUCE BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001683553 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 812154263 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2001 JUNIPERO SERRA BLVD., SUITE 640 CITY: DALY CITY STATE: CA ZIP: 94104 BUSINESS PHONE: (415) 294-1687 MAIL ADDRESS: STREET 1: 2001 JUNIPERO SERRA BLVD., SUITE 640 CITY: DALY CITY STATE: CA ZIP: 94104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-30 0 0001683553 SPRUCE BIOSCIENCES, INC. SPRB 0001822557 SIMPSON CAMILLA V C/O SPRUCE BIOSCIENCES, INC. 2001 JUNIPERO SERRA BLVD., SUITE 640 DALY CITY CA 94014 1 0 0 0 Common Stock 2021-04-30 4 M 0 14045 0.85 A 14045 D Common Stock 2021-04-30 4 S 0 14045 16.1384 D 0 D Stock Option (Right to Buy) 0.85 2021-04-30 4 M 0 14045 0.00 D 2027-10-18 Common Stock 16052 2007 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Represents a weighted-average sales price per share. These shares were sold in multiple transactions at prices ranging from $15.64 to $17.09. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. The shares subject to the stock option vest over a four-year period commencing October 19, 2017, with 1/4th of the shares vesting on October 19, 2018 and 1/36th of the remaining shares vesting on a monthly basis. /s/ Samir Gharib, Attorney-in-Fact 2021-05-04